NCT05551858View on ClinicalTrials.gov

Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Safety IssuesPainPancreas Fibrosis
Interventions
DRUG

Proglumide

(CAS: 6620-60-6.)

DRUG

Placebo

Avicel fiber filled capsule taken by mouth three times daily

Trial Locations (1)

20007

Georgetown University, Washington D.C.

All Listed Sponsors
lead

Georgetown University

OTHER